Drug intelligence / Profile preview

Pc2-d

Development stage: Preclinical
Modality: Small Molecules

Overview

Pc2-d is an amphiphilic carbohydrate-based Zinc(II)phthalocyanine (Zn(II)Pc) derivative being investigated as a photosensitizer for photodynamic therapy (PDT). Its mechanism of action involves the generation of singlet oxygen, which contributes to its photodynamic activity against human cancer melanoma cells. Structural modifications, such as the replacement of oxygen with sulfur at non-peripheral positions, influence its photophysical properties and binding affinity to human serum albumin (HSA).

Targets

^1O2 (Singlet oxygen)

Beyond the preview

Go deeper on Pc2-d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pc2-d.

Explore the full profile